Medical Use
Jesduvroq (daprodustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor used to treat anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least 4 months.
Limitations of Use: Jesduvroq has not been proven to improve quality of life, reduce fatigue, or enhance patient well-being. It is not intended as a substitute for transfusions in emergency anemia correction or for patients not on dialysis.
Recommended Dosage: Jesduvroq tablets can be taken with or without food and regardless of the use of iron or phosphate binders. Swallow the tablets whole without chewing, cutting, or crushing them. The timing of dialysis does not affect the administration of Jesduvroq. Dosage should be individualized to use the lowest effective dose to minimize the need for red blood cell transfusions, and hemoglobin levels should not exceed 11 g/dL.
If a dose is missed, take it as soon as possible unless it is close to the time of the next dose. In that case, skip the missed dose and take the next dose at the regular time. Do not take two doses to make up for a missed one.
Warning & Precautions
Iron Status: Assess iron levels in all patients before and during treatment with Jesduvroq (1 mg, 2 mg, 4 mg, 6 mg, and 8 mg). Administer supplemental iron if serum ferritin is below 100 mcg/mL or serum transferrin saturation is below 20%.
Thrombotic Events: Jesduvroq may increase the risk of serious arterial and venous thrombotic events, including stroke, venous thromboembolism, myocardial infarction, and vascular access thrombosis. Patients should seek immediate medical attention if they experience any symptoms of these conditions. Prompt evaluation and management are essential.
Heart Failure: Patients with a history of heart failure are at a higher risk of hospitalization for heart failure when taking daprodustat. Consider this risk when prescribing Jesduvroq and advise patients to report any worsening symptoms to their healthcare provider.
Hypertension: Daprodustat is contraindicated in patients with uncontrolled hypertension. Hypertensive crises, including seizures and hypertensive encephalopathy, may occur. Regularly monitor blood pressure and adjust or initiate antihypertensive therapy as needed.
Gastrointestinal Erosions: Jesduvroq and rhEPO-treated patients may develop gastric or esophageal erosions. This risk is higher in patients with a history of gastrointestinal erosion, peptic ulcer disease, or those using drugs that increase the likelihood of gastrointestinal erosion, as well as current alcohol drinkers and smokers.
Fetal Harm: Jesduvroq may cause fetal harm. Advise women not to breastfeed during treatment and for 7 days after the last dose. This medication is not recommended for patients with severe hepatic impairment.
Documentation Availability
Documents required to import JESDUVROQ to India?
JESDUVROQ (daprodustat) tablets can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing JESDUVROQ (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Jesduvroq®?
The generic name for Jesduvroq® is daprodustat.
Who manufactures Jesduvroq®?
Jesduvroq® is manufactured by GlaxoSmithKline.
Is Jesduvroq® FDA approved?
Yes, Jesduvroq® was approved by the FDA on February 1, 2023.
What dosage and form is Jesduvroq® available in?
Jesduvroq® is available as tablets in the following doses: 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg for oral administration.
What are the most common side effects of Jesduvroq®?
Common side effects include abdominal pain, hypertension, and thrombotic vascular events.
How much does Jesduvroq® cost in India?
The cost of Jesduvroq® in India can vary. To purchase it legally, you can reach out to Rx4u team.
What are the storage conditions for Jesduvroq®?
Store Jesduvroq® at 20-25°C (68-77°F), with allowed excursions between 15-30°C (59-86°F).
Is it safe to buy Jesduvroq® online in India?
Yes, you can safely purchase Jesduvroq® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
